Investors
Investors
The below is a link shows the forecasts that have been gathered for Haleon through Vuma Consensus, an external web-based tool independently managed by Vuma Financial Limited, a company separate from Haleon.
The consensus figures reflect the opinions of, and are updated by, investment analysts based on publicly available information. Haleon does not endorse, verify or express a view on the consensus estimates, and assumes no obligation to update or revise such information. Nothing in this analysis should be taken as a recommendation to buy or sell shares in Haleon, to take or not take any other action or to place any reliance on the information presented here.
Clicking on the below link confirms that you understand and accept the disclaimers set out above.
| Consensus* £'m (unless otherwise stated) |
Q1 25 No of estimates | Q1 2025 |
| Published | 22/04/2025 | |
| Group revenue | 13 | 2,848 |
| Group organic growth (%) | 13 | 3.2 |
| North America | 13 | 0.7 |
| EMEA & LatAm | 13 | 4.1 |
| Asia Pacific | 13 | 4.8 |
| Product category (%) | ||
| Oral Health | 12 | 6.6 |
| VMS | 12 | 2.8 |
| Pain Relief | 12 | 2.8 |
| Respiratory Health | 12 | - 1.2 |
| Digestive Health and Other | 12 | 3.1 |
Related
